Last reviewed · How we verify
HGP0919
At a glance
| Generic name | HGP0919 |
|---|---|
| Also known as | Tamiflu 75mg, Tamiflu Oral Suspension 6mg/mL |
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluating the Bioequivalence of HIP1403 and HGP0919 Suspensions (PHASE1)
- Evaluating the Bioequivalence of HIP1403, HGP0919 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HGP0919 CI brief — competitive landscape report
- HGP0919 updates RSS · CI watch RSS
- Hanmi Pharmaceutical Company Limited portfolio CI